| Active Not Recruiting | Induction FLOT With CROSS CRT for Esophageal Cancer NCT04028167 | University of Colorado, Denver | Phase 2 |
| Terminated | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcin NCT03722108 | UNICANCER | Phase 1 / Phase 2 |
| Unknown | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic an NCT04773769 | Auxilio Mutuo Cancer Center | N/A |
| Completed | Perioperative Chemo and Pembrolizumab in Gastric Cancer NCT02918162 | Gulam Manji | Phase 2 |
| Withdrawn | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph NCT03307941 | Jules Bordet Institute | Phase 1 / Phase 2 |
| Completed | Resilience and Exercise in Advanced Cancer Treatment NCT02680990 | Milton S. Hershey Medical Center | N/A |
| Terminated | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal NCT02485834 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitio NCT02443324 | Eli Lilly and Company | Phase 1 |
| Withdrawn | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced NCT02344810 | Eastern Cooperative Oncology Group | Phase 1 / Phase 2 |
| Completed | 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer NCT01939275 | City of Hope Medical Center | N/A |
| Terminated | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Wh NCT02234180 | Academic and Community Cancer Research United | Phase 2 |
| Completed | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab NCT02013154 | Leap Therapeutics, Inc. | Phase 1 |
| Unknown | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients Wit NCT02037048 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Posi NCT01855854 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Completed | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esop NCT01612546 | City of Hope Medical Center | Phase 2 |
| Terminated | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Meta NCT01705340 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer NCT01231399 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Juncti NCT01498289 | SWOG Cancer Research Network | Phase 2 |
| Unknown | Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction NCT01523015 | Medical University of Lublin | Phase 2 / Phase 3 |
| Completed | Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal NCT01472029 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Survivorship Care Plan for Gynaecological Cancer Patients NCT01582906 | Royal Marsden NHS Foundation Trust | — |
| Terminated | Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) NCT01395537 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy NCT01333033 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Validation of a Nutrition Screening Tool NCT01851928 | Royal Marsden NHS Foundation Trust | — |
| Completed | Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Sto NCT01360086 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Completed | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal NCT01212822 | Fox Chase Cancer Center | Phase 2 |
| Terminated | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer NCT01307956 | University of Nebraska | Phase 2 |
| Completed | Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer NCT01260701 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as NCT01123473 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gast NCT01178944 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gas NCT01216813 | Royal Marsden NHS Foundation Trust | — |
| Completed | Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With L NCT01107639 | Swiss Cancer Institute | Phase 3 |
| Completed | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Ad NCT00938470 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophag NCT00991952 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastr NCT00982592 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cance NCT00891878 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy NCT01243398 | University of Oxford | Phase 3 |
| Completed | Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, L NCT00757172 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Terminated | Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction NCT00732745 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery NCT01183559 | Fox Chase Cancer Center | Phase 1 |
| Completed | Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Canc NCT00978549 | Cambridge University Hospitals NHS Foundation Trust | Phase 3 |
| Completed | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Canc NCT00607594 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydroch NCT01561014 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophage NCT00253370 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach NCT01640782 | Mario Negri Institute for Pharmacological Research | Phase 3 |
| Completed | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroe NCT00084604 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carc NCT00084617 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer NCT00064259 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Sto NCT00061932 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Ju NCT00963092 | Cancer Research UK | — |
| Completed | Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer NCT00045526 | National Cancer Institute (NCI) | Phase 2 |
| No Longer Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors NCT04681248 | Leap Therapeutics, Inc. | — |